ABBV vs BMY
By Alex · Tickerpine
AbbVie Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | BMY |
|---|---|---|
| Price | $265.79 | $67.92 |
| Market cap | $469.68B | $138.74B |
| P/E ratio | 74.7 | 15.0 |
| ROE | — | 46.60% |
| Profit margin | 9.80% | 18.87% |
| Revenue growth | 10.20% | 5.70% |
| Dividend yield | 2.62% | 3.75% |
| Beta | 0.28 | 0.23 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs BMY in plain English
- ABBV is the bigger company — about 3.4× the market cap of BMY.
- BMY is cheaper on earnings (P/E 15.0 vs 74.7).
- ABBV is growing revenue faster (10% vs 6%).
- BMY has the higher dividend yield (3.75% vs 2.62%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.